Oct 31: Drug maker Zydus Cadila has received final approval from the USFDA to market Doxycycline Hyclate tablets USP, 100 mg.
According to the company, the drug is a broad spectrum antibiotic and is indicated to treat or prevent a variety of infectious disorders that are proven or strongly suspected to be caused by susceptible bacteria. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group has now more than 165 approvals and so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
Based in Ahmedabad, Zydus Cadila Group is a research-driven drug maker that discovers, develops, manufactures and markets a broad range of healthcare therapies.